Glaucoma is a chronic eye disease that affects millions of people worldwide and can lead to irreversible blindness if left untreated. While traditional glaucoma surgeries such as trabeculectomy and tube shunt surgery have been effective in reducing intraocular pressure (IOP), they also carry significant risks and potential complications. In recent years, emerging technologies and innovations in glaucoma surgery devices have aimed to provide safer and more effective options for glaucoma patients.

The glaucoma surgery devices market was estimated at US$ 1.75 billion in 2021 and is expected to grow at a CAGR of 7.03% during 2022-2028 to reach US$ 2.81 billion in 2028.

Emerging Technologies and Innovations in Glaucoma Surgery Devices are:

1.     Micro-Invasive Glaucoma Surgery (MIGS) Devices: MIGS devices are minimally invasive procedures that have been developed to treat glaucoma with lower risks and complications. These devices are designed to reduce IOP by creating new drainage pathways in the eye or enhancing existing ones. Examples of MIGS devices include iStent, Hydrus, and Xen Gel Stent.

2.     Endoscopic Cyclophotocoagulation (ECP) Devices: ECP is a minimally invasive laser procedure that uses an endoscope to deliver laser energy to the ciliary body of the eye, reducing its ability to produce aqueous humor, which can lead to a reduction in IOP. Examples of ECP devices include the MicroPulse P3 Glaucoma Device and the G-Probe.

3.     Laser-Assisted Cataract Surgery (LACS) Devices: LACS devices are used during cataract surgery to simultaneously treat glaucoma. These devices use lasers to remove the cloudy lens and reshape the cornea while also targeting the trabecular meshwork to improve drainage and lower IOP. Examples of LACS devices include the LenSx laser and the Catalys Precision Laser System.

4.     Drug Delivery Devices: Drug delivery devices have been developed to provide sustained and targeted delivery of glaucoma medications directly to the eye, reducing the need for frequent eye drops and improving patient adherence. Examples of drug delivery devices include the DURYSTA implant and the bimatoprost sustained-release implant.

The overall competitive landscape has been affected due to key strategic moves. The following are the major players in the glaucoma surgery devices market:

• Alcon, Inc.
• Glaukos Corporation
• Abbott Medical Optics
• Allergan Plc
• ASICO
• Carl Zeiss
• Katalyst Surgical
• Lumenis Ltd
• Ziemer Ophthalmic Systems AG
• Iridex Corporation

Request a sample here:

https://www.stratviewresearch.com/Request-Sample/3159/glaucoma-surgery-devices-market.html#form

In summary, emerging technologies and innovations in glaucoma surgery devices offer patients and doctors new options for treating this chronic eye disease with lower risks and potential complications. These technologies will continue to evolve and improve, ultimately providing safer and more effective treatment options for patients with glaucoma.